Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This cross-sectional study used data from the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) and machine learning algorithms to identify pediatric ophthalmologists based on physician coding patterns. A random forest model achieved an area under the receiver operating characteristic curve of 0.98, sensitivity of 0.98, and specificity of 0.88 when classifying pediatric eye specialists in the test validation cohort. Algorithm-based approaches to identify pediatric ophthalmologists using procedure codes may offer new avenues to determine the scope, scale, and trajectory of pediatric eye care delivery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885050 | PMC |
| http://dx.doi.org/10.1016/j.jaapos.2024.104052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dengue Epidemiology in 7 Southeast Asian Countries: 24-Year, Retrospective, Multicountry Ecological Study.
Interact J Med Res
September 2025
Department of Medicine, MacKay Medical College, New Taipei, Taiwan.
Background: Dengue fever remains the most significant vector-borne disease in Southeast Asia, imposing a substantial burden on public health systems. Global warming and increased international mobility may exacerbate the disease's prevalence. Furthermore, the unprecedented COVID-19 pandemic may have influenced the epidemiological patterns of dengue.
View Article and Find Full Text PDFUnderstanding the role of Shroom3 in the developing mouse myocardium.
PLoS One
September 2025
Children's Health Research Institute, Victoria Research Labs, London, Ontario, Canada.
Loss of actin cytoskeleton control can hinder integral developmental and physiological processes and can be the basis for a subset of developmental defects. SHROOM3 is an actin binding protein, best characterized as being essential for neural tube closure in vertebrates. Shroom3 expression has also been identified in the developing heart, with some associated congenital heart defects.
View Article and Find Full Text PDFPain, Agitation, Delirium, and Iatrogenic Withdrawal Syndrome Management in Children Who Are Critically Ill: Protocol for a European Clinical Practice Guideline Using the Grading of Recommendations Assessment, Development, and Evaluation Approach.
JMIR Res Protoc
September 2025
Institute of Higher Education and Research in Healthcare, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Background: In pediatric intensive care units, pain, sedation, delirium, and iatrogenic withdrawal syndrome (IWS) must be managed as interrelated conditions. Although clinical practice guidelines (CPGs) exist, new evidence needs to be incorporated, gaps in recommendations addressed, and recommendations adapted to the European context.
Objective: This protocol describes the development of the first patient- and family-informed European guideline for managing pain, sedation, delirium, and IWS by the European Society of Paediatric and Neonatal Intensive Care.
Gonorrhea and Chlamydia Screening for Adolescents and Young Adults in Emergency Departments.
JAMA Pediatr
September 2025
Department of Pediatrics and Emergency Medicine, Children's National Hospital, George Washington University, Washington, DC.
Importance: Adolescents account for almost half of the 2.5 million diagnosed sexually transmitted infections in the US annually, and the emergency department functions as the primary source of health care for many adolescents. No recommendations exist for emergency department gonorrhea and chlamydia screening.
View Article and Find Full Text PDFElinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).